New imaging combo could spot hidden breast cancers in dense tissue
NCT ID NCT03220893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 3,000 women with dense breast tissue to see if adding molecular breast imaging (MBI) to standard digital breast tomosynthesis (DBT) finds more invasive cancers. MBI uses a small amount of radioactive material to highlight active cells, like cancer. The goal is to improve early detection in women whose dense tissue can hide tumors on regular mammograms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio, 43623, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Phone-Based navigation could boost breast cancer detection in kenya
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a sticky film shield breast cancer patients from radiation burns in tropical heat?
- Can a simpler, cheaper method for marking breast tumors work as well as ultrasound?
- Could adding chemo help older breast cancer patients live longer? a major trial investigates.